Lessons from the withdrawal of rofecoxib.

Paul A Dieppe; Shah Ebrahim; Richard M Martin; Peter Jüni; (2004) Lessons from the withdrawal of rofecoxib. BMJ, 329 (7471). pp. 867-868. ISSN 1468-5833 DOI: 10.1136/bmj.329.7471.867
Copy

Patients would be safer if drug companies disclosed adverse events before licensing
Item Type Article
Keywords Anti-Inflammatory Agents, Non-Steroidal/*adverse effects, Cyclooxygenase Inhibitors/*adverse effects, *Drug Approval, Humans, Lactones/*adverse effects, Anti-Inflammatory Agents, Non-Steroidal, adverse effects, Cyclooxygenase Inhibitors, adverse effects, Drug Approval, Humans, Lactones, adverse effects
ISI 224566800001

Explore Further

picture_as_pdf
867.full.pdf
subject
Published Version
Available under Creative Commons: NC 3.0
View Download

Atom BibTeX OpenURL ContextObject in Span Multiline CSV OpenURL ContextObject Dublin Core Dublin Core MPEG-21 DIDL EndNote HTML Citation JSON MARC (ASCII) MARC (ISO 2709) METS MODS RDF+N3 RDF+N-Triples RDF+XML RIOXX2 XML Reference Manager Refer Simple Metadata ASCII Citation EP3 XML
Export

Downloads